Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Corsair Pharma
AddedFeb 15, 2024
UpdatedJun 18, 2026
Corsair Pharma

Corsair Pharma

Series B

Corsair Pharma: Innovating transformative therapies and prodrugs for enhanced patient treatment.

HQ
Sunnyvale, CA, US
Overview
Compare
Fundraising
Employees
Website

Corsair Pharma was founded with the mission to develop transformative solutions that enhance the therapeutic profile of medications, providing superior treatment options for patients. The company's vision centers on innovating prodrugs and delivery methods to improve patient outcomes. Corsair Pharma's primary focus is on a novel prodrug of treprostinil, delivered via a proprietary once-daily transdermal patch designed to treat pulmonary arterial hypertension (PAH). The company also explores the potential of this transdermal patch for other forms of pulmonary hypertension.

Notable individuals affiliated with Corsair Pharma include experts in pharmaceutical development and pulmonary diseases. The company has attracted significant interest from investors focused on innovative healthcare solutions. Key achievements include the development and initial testing of their transdermal patch, which promises to simplify treatment regimens and improve patient adherence. Corsair Pharma's impact lies in its potential to revolutionize PAH treatment, offering a more convenient and effective option for patients worldwide.

Corsair Pharma - Similar Companies

CSR Pharma Group logo

CSR Pharma Group

csrpharmsvcs.com

Concours Pharmaceuticals logo

Concours Pharmaceuticals

Corridor Pharmaceuticals logo

Corridor Pharmaceuticals

Cortria logo

Cortria

ARS Pharmaceuticals logo

ARS Pharmaceuticals

ars-pharma.com

United Therapeutics logo

United Therapeutics

Cascade Prodrug logo

Cascade Prodrug

cascadeprodrug.com

Bryn Pharma logo

Bryn Pharma

brynpharma.com

Vascarta logo

Vascarta

vascarta.com

Auxilius Pharma logo

Auxilius Pharma

auxiliuspharma.com

Transpire Bio logo

Transpire Bio

transpirebio.com

Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

amphastar.com

Tris Pharma logo

Tris Pharma

trispharma.com

APT Pharmaceuticals logo

APT Pharmaceuticals

Camino Pharma logo

Camino Pharma

caminopharma.com

Corsair Pharma - Quick Facts

Who are Corsair Pharma's competitors?

Companies similar to Corsair Pharma include CSR Pharma Group, Concours Pharmaceuticals, Corridor Pharmaceuticals and Cortria.

Where is Corsair Pharma's headquarters located?

Corsair Pharma's headquarters is located in Sunnyvale, CA, US.

When was Corsair Pharma's last funding round?

Corsair Pharma's most recent funding round was for $23M (USD) in September 2023.

How much has Corsair Pharma raised to-date?

As of Sep 20, 2023, Corsair Pharma has raised a total of $23M (USD).

How many employees does Corsair Pharma have?

Corsair Pharma has 7 employees as of Feb 4, 2024.

Corsair Pharma - Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Pharmaceuticals
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified